GET THE APP
A Medical Literature Review on Canagliflozin and Dapagliflozin and the Role of SGLT2 Inhibitors in Diabetic Management | Abstract
AgiAl Publishing House

The Open Access Journal of Science and Technology

Abstract

About the Journal Abstracting and Indexing Aim and Scope Author Guidelines Article Processing Charges Articles in Process Contact Information Disclosure Policy and Publication Ethics Editorial Board Editorial Workflow Archive
Google Scholar citation report
Citations : 409

The Open Access Journal of Science and Technology received 409 citations as per Google Scholar report

Flyer image
Indexed In
  • Genamics JournalSeek
  • Directory of Open Access Journals
  • Pollution Abstracts
  • Publons
  • International committee of medical journals editors (ICMJE)
  • Google Scholar
  • Chemical Abstract
View More
Awards Nomination

A Medical Literature Review on Canagliflozin and Dapagliflozin and the Role of SGLT2 Inhibitors in Diabetic Management

Author(s): Deepu Daniel and Natasha Bray

Diabetes is one of the most common diseases encountered in both the outpatient and inpatient settings. According to data from the 2011 National Diabetes Fact Sheet, approximately 8.3% (25.8 million) of the entire American population have diabetes. Of this population, about 72.9% (18.8 million) have been clinically diagnosed while an estimated 27.1% (7.0 million) remainundiagnosed.AccordingtothestudyEconomicCostsofDiabetesintheU.S.in2012,thetotalnationalcostofdiagnosed diabetes,includingdirectmedicalcostandreducedproductivitywasnearly$245billion.Extensiveresearcheffortshavegoneinto developing new pharmacologic agents to treat diabetes. The newest medications recently approved by the FDA are the SGLT2 inhibitors. This article will explain the mechanism of the action of this class of drugs along with their specific role in diabetic management.Thisarticlewillfocusoncanagliflozinanddapagliflozin,thetwomostwellresearchedandstudieddrugsofSGLT2 inhibitors,bothofwhichhavebeenapprovedforusebytheFoodandDrugAdministration.Someofthemajortrialsconcerning bothofthesedrugswillbepresentedinthisarticle.

<

Share this article